Envoy Medical ends $15 million ATM facility
Envoy Medical, Inc. has terminated its at-the-market equity facility, which had allowed the company to offer and sell up to $15 million of common stock from time to time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Envoy Medical, Inc. has terminated its at-the-market equity facility, which had allowed the company to offer and sell up to $15 million of common stock from time to time. The termination, effective June 24, 2026, also ends the related At The Market Offering Agreement dated January 17, 2025.
The company framed this step as reflecting confidence in its current capital position. Existing Class A common stock and redeemable warrants continue to trade on Nasdaq under the symbols COCH and COCHW, respectively.
8-K Event Classification
2 items: 1.02, 9.01
2 items
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
ATM facility size: $15 million
Common stock par value: $0.0001 per share
Warrant exercise price: $11.50 per share
+2 more
5 metrics
ATM facility size
$15 million
Maximum common stock that could be sold under the ATM Facility
Common stock par value
$0.0001 per share
Class A Common Stock
Warrant exercise price
$11.50 per share
Redeemable warrants for Class A Common Stock (COCHW)
Form type
Form 8-K
Current report on termination of material definitive agreement
ATM termination date
June 24, 2026
Effective date of at-the-market equity facility termination
Key Terms
At-the-Market (ATM) equity facility, Emerging growth company, Breakthrough Device Designation, investigational device, +1 more
5 terms
At-the-Market (ATM) equity facility financial
"announced that it has formally terminated its at-the-market equity facility (the “ATM Facility”)."
Emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Breakthrough Device Designation regulatory
"The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019."
A breakthrough device designation is a regulatory program that gives promising medical devices for serious or life‑threatening conditions priority support and faster review from a health authority (e.g., the U.S. FDA). Think of it as a “fast lane” or VIP pass through development and review: it can shorten time to market, lower regulatory uncertainty, and boost a company’s commercial prospects — but it is not an approval by itself.
investigational device regulatory
"the fully implanted Acclaim® cochlear implant, an investigational device."
An investigational device is a medical instrument, implant, or tool that is being tested in humans but has not yet received full regulatory approval for general use. Think of it as a prototype on a monitored test drive: investors watch these devices closely because trial results, safety findings, and approval decisions determine whether the product can reach patients, generate revenue, or create regulatory and commercial risk.
forward-looking statements regulatory
"This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Envoy Medical (COCH) announce in this 8-K filing?
Envoy Medical announced it has terminated its at-the-market equity facility and the related At The Market Offering Agreement, effective June 24, 2026. This facility had allowed periodic sales of common stock to raise capital as needed.
How large was Envoy Medical’s terminated ATM equity facility?
The terminated at-the-market equity facility had allowed Envoy Medical to offer and sell up to $15 million of its common stock. This capacity is no longer available following the termination effective June 24, 2026, as disclosed in the filing.
Why did Envoy Medical say it ended the ATM equity facility?
Envoy Medical stated that termination of the at-the-market equity facility reflects the company’s confidence in its current capital position. This suggests management believes existing resources are adequate without relying on this specific equity-raising tool.
Does Envoy Medical still have securities listed on Nasdaq after ending the ATM?
Yes. Envoy Medical’s Class A common stock continues to trade on Nasdaq under the symbol COCH, and its redeemable warrants, exercisable at $11.50 per share, trade under COCHW. The ATM facility termination does not affect these listings.
What are Envoy Medical’s key hearing implant products mentioned?
Envoy Medical highlights two core technologies: the Esteem fully implanted active middle ear implant, an FDA-approved device for moderate to severe sensorineural hearing loss, and the fully implanted Acclaim cochlear implant, which is an investigational device with FDA Breakthrough Device Designation.
Is Envoy Medical’s Acclaim cochlear implant already approved for general use?
No. The fully implanted Acclaim cochlear implant is described as an investigational device, limited by United States law to investigational use. It has FDA Breakthrough Device Designation but is still undergoing pivotal clinical and regulatory processes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
